VYNE Therapeutics Inc VYNE
News
VYNE Therapeutics to Participate in September Investor Conferences
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development